"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
| Descriptor ID |
D016190
|
| MeSH Number(s) |
D02.691.800.338
|
| Concept/Terms |
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
|
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in this website by year, and whether "Carboplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 5 | 6 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 11 | 12 |
| 2009 | 1 | 5 | 6 |
| 2010 | 1 | 4 | 5 |
| 2011 | 4 | 15 | 19 |
| 2012 | 3 | 2 | 5 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 5 | 6 |
| 2016 | 4 | 3 | 7 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 9 | 10 |
| 2019 | 1 | 7 | 8 |
| 2020 | 1 | 4 | 5 |
| 2021 | 5 | 10 | 15 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 5 | 7 |
| 2025 | 2 | 5 | 7 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. Nat Commun. 2026 Mar 19; 17(1).
-
Association of platinum-based chemotherapy with survival in ovarian carcinosarcoma: a retrospective 2-center cohort study. Int J Gynecol Cancer. 2026 06; 36(6):104440.
-
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer. Breast Cancer Res Treat. 2025 Oct; 213(3):347-354.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
-
Targeting the oncoprotein RLIP as novel therapy for ovarian cancer. J Ovarian Res. 2025 Jul 12; 18(1):150.
-
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. Clin Lung Cancer. 2025 Nov; 26(7):541-551.
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
-
Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis. 2024 09 11; 45(9):696-707.
-
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 2024 09 01; 10(9):1212-1219.